

difficult to wear for extended periods and often must leave the room to remove the device and “catch their breath” before returning into respiratory isolation, a finding suggested by others.²

After discovering the cost savings, we opted to continue to use the HEPA respirator at our hospital, despite the revised OSHA guidelines that allowed use of cheaper respirators. However, in recent months, healthcare worker preference for the cheaper (and decidedly more comfortable) N-95 units has resulted in a gradual shift to these devices. We continue to monitor the cost of the PPE program, but feel strongly that safety—not cost—must be the single determinant when selecting proper equipment for worker protection against tuberculosis or any potential occupationally acquired pathogen. In that regard, the best respirator is the respirator that people will wear.

REFERENCES

- Centers for Disease Control and Prevention. Tuberculosis morbidity—US, 1994. *MMWR* 1995;44:387-395.
- Segal-Maurer S, Kalkut GE. Environmental control of tuberculosis: continuing controversy. *Clin Infect Dis* 1994;19:299-308.
- Decker MD. Respiratory protection standard: comments on OSHA's proposed revision. *Infect Control Hosp Epidemiol* 1995;16:365-371.
- Adal KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM. The use of high efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. *N Engl J Med* 1994;331:169-173.
- Nettleman MD, Fredrickson M, Good NL, Hunter SA. Tuberculosis control strategies: the cost of particulate respirators. *Ann Intern Med* 1994;121:37-40.
- Centers for Disease Control and Prevention. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care facilities, 1994. *MMWR* 1994;43:1-132.
- Hedrick E. TB to be dropped from revised OSHA respiratory protection standard. *APIC News* 1995;14:1-2.
- Pugliese G. New TB respirators expected to save millions. *Infect Control Hosp Epidemiol* 1995;16:555.
- Fella P, Rivera P, Hale M, Siegal M, DeHovitz J, Sepkowitz KA. Implementation of OSHA guidelines for protection of employees against TB at a NYC hospital. *Infect Control Hosp Epidemiol* 1994;15:358. Abstract #L1.
- Rivera P, Campbell A, Louthier J, Hale M, DeHovitz J, Sepkowitz KA. Fit-testing for HEPA-respirators at a NYC hospital. *Am J Infect Control* 1995;23:114.
- Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis to health-care workers among HIV-infected persons—Florida and New York. *MMWR* 1991;40:585-591.
- Fella P, Rivera P, Hale M, Squires K, Sepkowitz KA. Dramatic decrease in tuberculin skin test conversion rate among employees at a hospital in New York City. *Am J Infect Control* 1995;23:352-356.

Vibrio fluvialis and Leech Therapy

by Gina Pugliese, RN, MS
Martin S. Favero, PhD

For centuries, leeches have been used in medicine for blood-letting, wound draining, and healing. Most recently, the use of medicinal leeches has increased in the field of plastic surgery for venous insufficiency in previously devascularized tissue or failing flaps.

In a recent case report, the use of leech therapy to treat postsurgical

venous congestion in a patient following oral reconstructive surgery for mouth cancer led to a wound infection with *Vibrio fluvialis*—an intestinal pathogen. This is the first reported case of wound infection caused by *V fluvialis* associated with medicinal leech therapy. The most common reported pathogen causing infections associated with medicinal leech therapy is *Aeromonas hydrophilia*, a gram-negative rod that is part of the normal gut flora of leeches and

assists in digestion.

The authors recommend that leech therapy should be reserved for cases in which surgical correction is not possible or for the temporary alleviation of venous congestion while the patient is waiting for definitive surgical intervention.

FROM: Varghese MR, Farr RW, Wax MK, et al. *Vibrio fluvialis* wound infection associated with medicinal leech therapy. *Clin Infect Dis* 1996; 22:709-710.